VBI Vaccines Inc. [VBIV] took an upward turn with a change of 17.71%, trading at the price of $0.79 during the trading session on Thursday. The price movement in correlation with percentage of the mentioned increase can allow a valuable insight to investors. During the last trading session 11.04 million shares changed hands being bought and sold, while VBI Vaccines Inc. shares have an average trading volume of 891.26K shares for that time period. VBIV monthly volatility recorded N/A, in the meanwhile having share price volatility for the week set at N/A. PS value for VBIV stocks is 21.78 with PB recorded at 0.89.

VBI Vaccines Inc. [NASDAQ:VBIV]: Analyst Rating and Earnings

Stock market traders frequently keep their eyes on what Wall Street experts as it relates to a potential investment. For VBI Vaccines Inc. [VBIV], the most recent analyst consensus recommendation available since its latest financial results for the quarter ending in December. On average, stock market experts give VBIV an Buy rating. Its stock price has been found in the range of 0.57 to 3.31. This is compared to its latest closing price of $0.67.

Wall Street analysts provide their ratings on a scale of 1 to 5, and the current average score for VBI Vaccines Inc. [VBIV] is sitting at 1.33. This is compared to 1 month ago, when its average rating was 1.50.

Keep your eyes peeled for the soon-to-be-published financial results of this company, which are expected to be made public on Thu 25 Jul (In 36 Days).

Fundamental Analysis of VBI Vaccines Inc. [VBIV]

Now let’s turn to look at profitability: with a current Operating Margin for VBI Vaccines Inc. [VBIV] sitting at -1792.25 and its Gross Margin at -34.40.

Turning to investigate this organization’s capital structure, VBI Vaccines Inc. [VBIV] has generated a Total Debt to Total Equity ratio of 14.29. Similarly, its Total Debt to Total Capital is 12.51, while its Total Debt to Total Assets stands at 10.19. Looking toward the future, this publicly-traded company’s Long-Term Debt to Equity is 13.17, and its Long-Term Debt to Total Capital is 11.53.

What about valuation? This company’s Enterprise Value to EBITDA is -2.35. The Enterprise Value to Sales for this firm is now 39.57, and its Total Debt to Enterprise Value stands at 0.23. VBI Vaccines Inc. [VBIV] has a Price to Book Ratio of 1.59.

Shifting the focus to workforce efficiency, VBI Vaccines Inc. [VBIV] earns $29,955 for each employee under its payroll. Similarly, this company’s Receivables Turnover is 33.72 and its Total Asset Turnover is 0.02. This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 2.60 and its Current Ratio is 2.64. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.

VBI Vaccines Inc. [VBIV] has 97.66M shares outstanding, amounting to a total market cap of $77.05M. Its stock price has been found in the range of 0.57 to 3.31. At its current price, it has moved down by -76.14% from its 52-week high, and it has moved up 37.20% from its 52-week low.

This stock’s Relative Strength Index (RSI) is at 20.23. This stock, according to these metrics, is currently Oversold.

Conclusion: Is VBI Vaccines Inc. [VBIV] a Reliable Buy?

VBI Vaccines Inc. [VBIV] stock is presenting a less attractive investment opportunity when compared to similarly-sized corporations in the same industry. The price performance of these shares has not shown much promise, and the financial results that this company has recently delivered present a highly risky investment.